Analyses suggest that ribociclib improves progression-free survival across most intrinsic subtypes of HR-positive/HER2-negative disease, and overall survival benefits with the drug are still evident at about 4.5 years of follow-up.
Results from the RxPONDER trial suggest some breast cancer patients can forgo chemotherapy – specifically, postmenopausal women with hormone receptor–positive, HER2-negative breast cancer who have one to three involved nodes and a 21-gene recurrence score of 25 or less.
Women with breast cancer who were receiving financial assistance through a national charity prioritized either affordability or maintaining functional independence when making treatment decisions.
Two trials suggest we must be somewhat concerned about the chemotherapy partner used with an immune checkpoint inhibitor in patients with advanced triple-negative breast cancer (TNBC) expressing programmed death–ligand 1 (PD-L1).
Adjuvant endocrine therapy alone may be insufficient for some younger women with luminal breast cancer, based to an unplanned analysis of the phase 3 MINDACT trial.
In 2016, an opinion piece published in the journal Nature threw cold water on the concept of precision oncology — tailoring the treatment of individual patients to the genetic characteristics of their tumors.
Combination therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor and an aromatase inhibitor (AI) has the same good efficacy but greater toxicity in women with hormone receptor (HR)–positive, HER2-negative advanced breast cancer who are aged 75 years or older, a pooled analysis of randomized controlled trials concluded.
mTOR inhibitor vistusertib plus fulvestrant was inferior to everolimus plus fulvestrant in a randomized clinical trial including women with advanced breast cancer, investigators have reported.
